Cipla to conduct study on Paxlovid https://ift.tt/nVY50um

In its meeting held this week, the SEC granted approval to the company to conduct bioavailability and bio equivalence (BA/BE) studies. “Cipla will carry study on 44 participants and soon share data with the regulatory authority,” a government official said.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/dwH3NGJ